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Abstract The concept that extracellular vesicles may act
as paracrine/endocrine effectors is based on the evidence
that they are able to transport bioactive molecules between
cells, either within a defined microenvironment or remo-
tely, by entering the biologic fluids. Extracellular vesicles,
including exosomes and microvesicles, may deliver lipids
and various functional transcripts, released from the cell of
origin, to target cells. Since extracellular vesicles contain
defined patterns of mRNA, microRNA, long non-coding
RNA, and occasionally genomic DNA, they may transfer
genetic information which induces transient or persistent
phenotypic changes in recipient cells. In this review, we
will discuss potential physiologic and pathological impli-
cations of extracellular vesicles, as well as the diagnostic
and therapeutic opportunities that they may provide.
Keywords Exosomes  Microvesicles  MRNA 
MicroRNA
Introduction
Cells are required to communicate with each other for
appropriate development and functioning of tissues. Clas-
sical means of cell communication are represented by cell
junctions, adhesion contacts, and soluble factors that can
act upon the same cell where they are produced, or upon
neighboring cells, or may even act over long distances in
an endocrine manner [1]. In addition to these described
means, another mechanism of cell communication has
recently emerged, namely communication by extracellular
vesicles (EVs). EVs are released by numerous cell types
such as blood cells, dendritic cells, endothelial and epi-
thelial cells, nervous cells, tumor cells, and embryonic and
adult stem cells in the extracellular space, both in physio-
logic and pathological conditions. EVs have also been
identified in body fluids such as serum, saliva, amniotic
fluid, synovial fluid, breast milk, and urine [2–7]. Cell
communication by means of EVs is described as being a
universal way for cells to interact with each other and
influence the behavior of other cells by exchanging mate-
rial and information.
EVs are cytosol fragments with spheroid morphology
surrounded by a membrane composed of a lipid bilayer
and hydrophilic proteins, similar to the cell plasma
membrane. EVs are a heterogeneous group of vesicles,
known in the literature by several different names (micr-
ovesicles, microparticles, ectosomes, exosomes, shedding
vesicles, etc.), with sizes ranging from 30 to 1,000 nm.
They are constitutively produced in vitro or in vivo by
cells, or following the activation by soluble agonists or
physical or chemical stress, including oxidative stress,
hypoxia, and shear stress [8]. Since EVs carry receptors,
bioactive lipids, proteins, and, most importantly, nucleic
acids, such as mRNA and microRNA (miRNA), they are
able to deliver important information to recipient cells.
The delivery of mRNA to target cells is followed by
subsequent transcription and production of functional
proteins. Moreover, functional miRNA may interfere with
the production of target proteins within recipient cells.
Consequently, EVs may modify the phenotype and func-
tions of target cells.
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The exact process of EV formation is currently not fully
elucidated. The previous classification of EVs into the two
major groups of shedding vesicles and exosomes on the
basis of their different biogenesis, size, and protein com-
position is presently controversial, and recent studies have
questioned its validity.
It has been suggested that shedding vesicles may originate
by direct budding from the cell plasma membrane into the
extracellular space in a calcium-dependent process with
cytoskeleton reorganization, curvature-mediated lateral
redistribution of membrane components, leading to the cre-
ation of rafts and membrane nanodomains and formation of
plasma-mediated attractive forces between membranes [9].
The instrumental role of sphingomyelinases (SMases)
has been reported in the mechanism of EV release. It has
recently been demonstrated that acidic-SMase (A-SMase)
is involved in microparticle release in glial cells, and thus
represents a crucial role in EV release. A-SMase activity
triggers microparticle release from glial cells [10].
On the other hand, exosomes are thought to originate from
the endosomal membrane cell compartment, and their release
is said to be consequential to the exocytosis of multivesicular
bodies and discharge into the extracellular space of intralu-
minal vesicles after fusion with the plasma membrane, in a
p53-controlled process, and is dependent on cytoskeleton
activation, but independent of cell calcium concentration. In
addition, some studies have suggested that the multiprotein
complex, Endosomal Sorting Complexes Required for
Transport (ESCRT), has a critical role in the sorting of vesi-
cles, and the finding of certain components of the ESCRT
complex in exosomes, such as Alix and Tsg101, has raised the
possibility that the ESCRT machinery could be involved in the
formation and exocytosis of these vesicles [11, 12].
Trajkovich et al. [13] have recently suggested a different
pathway for intra-endosomal membrane transport and exo-
some formation in a mouse oligodendroglial cell line,
independent of the ESCRT machinery, but requiring sphin-
golipid ceramide. Ceramide is one of the major lipids in the
lipid bilayer of cell membranes and is produced after
hydrolysis of sphingomyelin, catalyzed by SMases, and used
for the generation of intraluminal vesicles of multi-vesicular
bodies that are not intended for transfer to lysosomes and
subsequent degradation, but are released as exosomes [13].
Van Niel et al. [14] suggested that, in melanocytes, the
CD63 tetraspanin accounts for an ESCRT- and ceramide-
independent mechanism of EV sorting. In the biogenesis of
melanosomes, this ESCRT-independent sorting regulated
by CD63 tetraspanin could coexist with an ESCRT-
dependent mechanism for predetermining the premelano-
some protein, PMEL, for extracellular release via exosomes
or for lysosome degradation [14].
A CD63 association has also been described for the viral
oncogene latent membrane protein 1 (LMP1) in endosomes
with low cholesterol concentrations that are released as
exosomes to antagonize downstream NF-jB activation in
Epstein Barr virus (EBV) infection of human B cells [15].
This study suggests an exploitation of distinct membrane
subdomains by EBV-encoded LMP1, i.e., the aggregation of
LMP1 in cholesterol-rich membranes of Golgi compart-
ments to induce NF-jB activation, and the association of
LMP1 with CD63 in microdomains, leading to the accu-
mulation in intraluminal vesicles and consequent transfer, as
exosomes, to outside the cell to prevent NF-jB activation.
Fang et al. [16] described a sorting pathway of exosomal
proteins in Jurkat T cells, where protein selection was
achieved on the basis of higher-order oligomerization and
plasma membrane association, suggesting that this higher-
order oligomerization was sufficient to target plasma
membrane proteins to exosomes. Since higher-order olig-
omerization is a primary determinant of HIV Gag budding,
they proposed a biogenesis similar to that of exosomes for
HIV and other retroviruses [16].
Composition of EVs
Many studies in the literature point to differential molec-
ular expression by the two main classes of EVs, shedding
vesicles and exosomes [17]. Shedding vesicles bear high
concentrations of cholesterol and phosphatydilserine, along
with molecules usually recognized in lipid rafts such as
flotillin-1, but their molecular composition is highly het-
erogeneous, according to the various cells from which they
originate. Tumor cells and neutrophils produce EVs enri-
ched in proteolytic enzymes and metalloproteinases to
degrade extracellular matrix. Platelets generate EVs car-
rying molecules, such as P-selectin, integrins, and GPIb
and GPIIB-IIIa glycoproteins, critical for coagulation [17].
Conversely, exosomes show molecules on their surface,
such as Alix, Tsg101, Hsc70, CD63, CD81, and CD9,
thought to be distinctive of exosomes, as well as low
amounts of phosphatydilserine.
However, the EVs produced by cells in the cell super-
natant or present in extracellular fluids are inexorably a
heterogeneous population of both shedding vesicles and
exosomes, and it is currently very difficult to accurately
discriminate between the two vesicle types.
Functions of EVs
EVs can be internalized by recipient cells following
receptor-ligand interactions and the varied assortment of
bioactive molecules, derived from the cell of origin, such
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as proteins, bioactive lipids, and nucleic acids, can be
transferred along with the proteins expressed on the EV
surface.
EVs may directly activate the recipient cell by acting as
signaling complexes [1, 17]. In fact, EVs derived from
macrophages bind to platelets by means of the P-selectin
glycoprotein ligand-1 expressed on their surface and EVs
from neutrophils expressing Mac-1 may induce platelet
activation.
EVs may also transfer receptors from one cell to
another. Quah et al. [18] have demonstrated that bystander
B cells can rapidly acquire antigen receptors from activated
B cells by membrane transfer with the resulting increase of
a cell population presenting a specific antigen to CD4 T
cells. Also, Fas ligand can be transferred from tumor cells
by EVs provoking activated T cell apoptosis [19]. In
addition, tumor cells may transfer Tissue Factor (TF) and
oncogenic receptors such as EGFRvIII to neighboring
endothelial cells, via EVs, thus potentiating tumor angio-
genesis [20, 21].
Moreover, EVs may convey proteins to the cytoplasm of
recipient cells, such as the cell death caspase-1 message
conveyed by microvesicles derived from LPS-stimulated
monocytes [22], or the tumor exosome-carried Notch
ligand Delta-like 4 which inhibits Notch signaling,
enhancing angiogenesis [23].
Recent studies have also reported the release of EVs
from neurons to glial cells, as well as their presence in
cerebrospinal fluid [24, 25]. Al-Nedawi et al. [26] dem-
onstrated that glioblastoma multiforme tumor cells
expressing the truncated and oncogenic variant of the
epidermal growth factor receptor can transfer this receptor
to other cells, via microvesicles, in this way propagating
the oncogenic phenotype. In the central nervous system, it
has been suggested that some proteins such as beta-amy-
loid peptide, prion protein, tau, and alfa-synuclein are
transferred via exosomes, thus avoiding degradation and
favoring the deposition of pathogenic aggregates in neu-
rodegenerative diseases (Alzheimer Disease, Tauopathies,
prion disease, and Parkinson Disease) [27]. In addition,
exosomes may contribute to the diffusion of prions [28].
The most interesting aspect of EV function is their
involvement in the transfer of genetic information. In
addition to bioactive proteins and lipids, EVs also contain
nucleic acids such mRNA and miRNA, thus protecting
them from extracellular degrading enzymes. In particular,
the horizontal transfer of miRNAs has been proposed as a
new form of intercellular communication, representing a
means by which donor cells can regulate gene expression
of recipient cells [29]. In fact, miRNAs are 19–23 nucleotide-
long non-coding RNAs known as critical post-transcrip-
tional modulators of gene expression. Present both in
plants and metazoans, miRNAs are able to induce
inhibition or degradation of target mRNAs, thus influenc-
ing many processes of cell homeostasis, such as survival,
proliferation, and cell differentiation, as well as metabo-
lism and tumorigenesis processes [30]. In mammals,
miRNAs play the role of finely regulating and controlling
about half of their mRNAs. Hundreds of mRNAs can be
targeted by a single miRNA, and one mRNA can be
repressed by different miRNAs in a complex interrelated
network. In the nucleus, one particular RNase III family
member, Drosha, converts primary miRNA transcripts into
70-nucleotide-long pre-miRNA [30]. Exported from the
nucleus into the cytoplasm by exportin 5, the pre-miRNA is
then cleaved by the RNase III Dicer to generate a mature
miRNA duplex, approximately 22-nucleotides long. Some
miRNAs are created by a process of splicing and debran-
ching, bypassing the Drosha step in the nucleus, but still
involving cleavage by Dicer in the cytoplasm. In the fol-
lowing steps, the guide strand of the miRNA duplex is
integrated into the miRNA-induced silencing complex
(miRISC), while the passenger strand is degraded. Arg-
onaute 2 (Ago2) protein is a core component of miRISC
and directly cooperates with miRNAs in the repression of
target mRNAs [30]. The cytoplasmatic foci known as
processing bodies and stress granules are dynamic struc-
tures where the translationally repressed mRNAs can be
accumulated while waiting to be recycled or degraded.
Both of these foci essentially share some components of
the miRISC complex [30]. Interestingly, EVs contain
components of the miRISC complex, such as Ago2, toge-
ther with several RNA-binding proteins known to regulate
RNA traffic between the nucleus and the cytoplasm. It can
be therefore hypothesized that, during EV biogenesis, these
RNA binding proteins regulate the accumulation of selec-
ted RNAs within EVs. Studies on the transfer of reporter
mRNAs and their translation into proteins, demonstrated
both in vitro and in vivo, suggest that the mRNA delivered
by EVs is functional [31–33]. The presence of miRNAs
inside exosomes derived from mouse and human mast cells
was shown by Valadi et al. [34]. In addition, Yuan et al..
[35] demonstrated the in vitro transfer of miRNAs to
murine embryonic fibroblasts by EVs. We have charac-
terized miRNAs critical for cell survival and differentia-
tion, as well as multi-organ development and immune
system regulation in EVs from human mesenchymal stem
cells. These miRNAs can be transferred by EVs to recipient
cells and can modulate the expression of target proteins
[36, 37].
Recent studies suggest that EVs can also contain DNA.
Waldenstro¨m et al. [38] showed that, in addition to mRNA,
EVs derived from cultured adult murine cardiomyocytes
can also transfer chromosomal DNA to fibroblasts, con-
firming the previous data demonstrating the occurrence of
DNA in human prostasomes [39]. Guescini et al. [40] also
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reported that exosomes derived from astrocytes and glio-
blastoma cells can carry mitochondrial DNA.
Effect of EVs in immune response, tumor, and stem
cell biology
The miRNAs expressed by cells of the immune system may
influence pathways controlling the development and role of
innate and adaptive immune responses, and they may be
dysregulated in cancers, thus acting as tumor suppressors or
oncogenes [41]. The findings that Epstein-Barr virus-trans-
formed B lymphocytes produced exosomes expressing MHC
class II dimmers, and were able to present them to T cells
[42], and that dendritic cell-derived exosomes expressing
MHC class I–peptide complexes can induce CD8?T-lym-
phocyte-dependent antitumor immune responses in mice
in vivo [43] both suggest that exosomes could be critical
modulators of the adaptive immune response. The message
delivered by exosomes differs depending on the physiologic
state of the cell from which they derive [44, 45]. Only
recently it has been suggested that miRNAs delivered by EVs
could play a role in immune system regulation [46]. In fact,
an EV-dependent exchange of miRNAs between APC and T
cells occurs at the site of immune synapses [47]. It has been
shown that EVs are directly involved in the cognate DC–T
cell interaction [48]. These studies suggest the involvement
of a dynamic exchange of information between DCs and T
cells through EVs [46].
EVs have been also implicated in the modulation of the
tumor microenvironment. Indeed, tumor-derived EVs may
inhibit the immune response, thus favoring the tumor cell
escape from immune surveillance [49] by inducing apop-
tosis in immune effectors such as NK cells and cytotoxic T
lymphocytes (CTLs). In addition, EVs derived from human
prostate cancer cells transport the Fas ligand, which may be
transferred to CTLs, favoring their apoptosis [50].
Moreover, tumor-derived EVs may induce phenotypic
changes in stromal cells that favor tumor invasion and
dissemination [51]. Specifically, EVs may promote the
exchange of receptors, active proteins, lipids, or genetic
information between tumor and stromal cells; for example,
tumor-derived EVs may enhance tumor invasion by
delivering interleukin-8 and chemokines [52] or matrix
metalloproteinases (MMP) and extracellular MMP inducer
[51] to neighboring cells. The horizontal propagation, via
EVs, of the oncogenic form of epidermal growth factor
receptor EGFRvIII from highly aggressive to non-aggres-
sive glioma cells may promote tumor growth and invasion
[26]. Several other transcripts capable of favoring tumor
invasion and metastasis were shown to be transferred from
cancer to stromal cells, such as transglutaminase and
fibronectin [53] and Delta-like ligand 4 [23].
In addition, EVs may transfer genetic information
(mRNA, miRNAs, and oncogenes) from tumor cells,
capable of reprogramming normal stromal and endothelial
cells. The phenotype of tumor-associated monocytes has
been shown to depend on the transfer of tumor mRNA [54].
As shown by Skog et al. [55], glioblastoma-derived EVs
may transfer specific and functional mRNA and miRNAs
capable of inducing activation of cell migration, angiogenesis,
and proliferation in brain microvascular cells. EVs derived
from other tumors such as colorectal[56], lung [57], and
prostate cancer cells [58] alter the phenotype of normal cells
by transferring specific RNA subsets. On the other hand, EVs
released from the surrounding cells may modify cancer cell
gene expression [58]. EVs derived from cancer stem cells
were shown to contain pro-angiogenic RNAs able to induce a
premetastatic niche in the lungs, whereas those derived from
differentiated cancer cells were not able to induce this niche,
and their mRNA and miRNA content differs [59]. EVs from
cancer stem cells contained miR-29a, miR-650, and miR-151,
all associated with tumor invasion and metastases, along with
miR-19b, miR-29c, and miR-151, known to be upregulated in
patients with renal carcinomas [59].
Another emerging field on the role of EVs is in stem cell
biology. Studies by Ratajczak et al. [60] demonstrated that
EVs derived from embryonic stem cells are involved in the
maintenance of pluripotency and the undifferentiated phe-
notype of stem cells. It has been subsequently shown that
EVs from embryonic stem cells are enriched in miRNAs
which can be transferred in vitro to murine embryonic
fibroblasts [35]. Adult stem/progenitor cells may also exploit
EVs to convey genetic information. We found that EVs
released from endothelial progenitor cells may transfer a
specific subset of mRNA, associated with angiogenic path-
ways, to quiescent endothelial cells, capable of activating an
angiogenic program in these cells [31]. Subsequent studies
based on silencing of Dicer to generate miRNA-depleted
EVs, or on selective inhibition of angio-miRNAs (miR 126
and miR 296) demonstrated that the angiogenic effect of EVs
released by endothelial progenitor cells are mainly depen-
dent on miRNA transfer [61]. Quesenberry et al. [62] have
suggested a continuum model of stem cell biology in which
EVs convey information determinant for stem cell differ-
entiation. According to this theory, EVs, in concert with the
cell cycle transit of stem cells, are critical factors for mod-
ulation of stem cell plasticity.
EVs as a diagnostic tool
Based on the evidence that EVs are present in blood and other
biologic body fluids, EVs can be regarded as potential easily
accessible diagnostic biomarkers for many pathological
conditions, including metabolic diseases such as type II
14 Endocrine (2013) 44:11–19
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diabetes and obesity [63]. Patients with type II diabetes show
an increased amount of platelet- and monocyte-derived EVs
[64]. In particular, the number of EVs is elevated in diabetic
nephropathy [65, 66]. An elevated number of platelet-
released EVs have also been reported in diabetic patients
after acute myocardial infarction, compared with non-
diabetic subjects with myocardial infarction [67]. The urinary
level of EV-associated dipeptidyl peptidase-IV in type II
diabetic patients was found to be higher than in normal
subjects, suggesting that these EVs could be exploited as
specific biomarkers for the onset of diabetic nephropathy
[68]. Muller et al. [69] proposed that insufficient lipid
accumulation and lipid droplet biogenesis with defective
conversion from small to large adipocytes in obesity is
related to a defect of EV-mediated communication.
Several studies have addressed the potential use of EVs
as biomarkers in cancer as their level in circulation cor-
relates with a poor prognosis. Mucin-expressing EVs are
potential markers for early detection of adenocarcinomas
[70]. Moreover, patients with melanoma have high levels
of exosomes expressing CD63 and caveolin-1 in plasma, as
detected by sandwich ELISA [71].
Circulating EVs were shown to contain tumor-specific
mRNA in glioblastoma [55], as well as in gastric [72] and
breast [73] carcinomas. In particular, the miRNA profile of
EVs can be useful for diagnostic purposes in cancer [74].
For example, the profile of miRNA may vary with the
disease stage in ovarian cancer [75], and may have a
diagnostic potential in lung adenocarcinoma [76].
EVs present in urine could be also used as a biomarker.
EVs in urine of patients with prostate cancer express mRNA
encoding PCA3 and the TMPRSS2:ERG fusion products
which are up-regulated in cancer cells [7]. Several diagnostic
products based on EVs/exosomes have recently been devel-
oped by commercial companies [77]. Exosome Sciences has
developed an ELISA test for identification of exosomes in
HIV, tuberculosis, and cancer (www.AethlonMedical.com).
The Exotest based on an ELISA platform is under develop-
ment for neurodegenerative and cancer diseases by Hansa-
BioMed (www.HansaBioMed.eu). Exosome Diagnostic has
created an EV-based platform, mainly for cancer diagnostic
purposes (www.ExosomeDX.com). Caris Life Sciences has
focused on a sensitive EV-based diagnostic test for prostate
cancer (www.CarisLifeSciences.com). In summary, the use
of EVs as a diagnostic tool may provide an easy and non-
invasive way to detect tissue-derived markers specific for the
cell of origin.
Therapeutic potential of stem cell-derived EVs
The concept that EVs can modulate the phenotype of target
cells by transferring extracellular RNAs is an emerging
paradigm in intercellular communication. According to this
view, extracellular RNAs are now considered as paracrine/
endocrine signals. EVs contain diverse species of RNAs
including mRNA, miRNAs, and long non-coding RNAs
that reflect the functional state of the cell of origin.
Therefore, several studies have evaluated whether stem
cell-derived EVs may mimic stem cell functions. Recent
studies on adult stem cell-induced tissue regeneration point
to paracrine/endocrine mechanisms rather than permanent
engraftment and trans-differentiation of stem cells. There-
fore, the paracrine/endocrine hypothesis has changed the
perspective of the therapeutic use of stem cells in regen-
erative medicine. Several studies indicate that EVs play a
relevant role as mediators of stem cell-induced regenera-
tion by reprogramming injured cells.
In experimental acute kidney injury, EVs derived from
MSCs were shown to mimic the beneficial effects of stem
cell treatment by reprogramming injured tubular epithelial
cells to a stem cell-like phenotype by triggering a regener-
ative program [78]. While EV-transferred mRNA can be
translated into proteins, the miRNAs are post-transcriptional
regulators which may induce epigenetic changes in recipient
cells. In these experimental conditions, EVs were shown to
accumulate at the site of tissue injury and to transfer MSC-
specific functional RNAs including regulators of transcrip-
tion capable of altering gene expression in recipient cells,
such as upregulation of BCL-XL, BCL2, and BIRC8 anti-
apoptotic genes, and downregulation of CASP1, CASP8, and
LTA genes involved in cell apoptosis [79]. The renopro-
tective action of EVs derived from endothelial progenitor
cells in renal acute ischemia reperfusion injury was mainly
ascribed to the transfer of pro-angiogenic miRNAs [61]. EVs
derived from endothelial progenitor cells were also found to
improve neovascularization and muscle regeneration in a
model of hind limb ischemia [80]. In pig and mouse models
of acute infarction, EVs were shown to limit the infarct size
and favor recovery [81].
The biologic effects of EVs, however, not only depend
on their content but also on the metabolic and functional
state of recipient cells. In fact, the delivery of miRNAs may
have differential effects on injured, normal, or neoplastic
cells depending on which pathways are activated in the
recipient cells (Fig. 1). For instance, EVs derived from
human liver stem cells may activate regenerative programs
in hepatocytes, favoring liver regeneration after 70 %
hepatectomy in rats [82]. Conversely, the same EVs may
reprogram HepG2 hepatoma and primary hepatocellular
carcinoma cells (HCC) by inhibiting their growth and
survival, leading to regression of ectopic tumors developed
in SCID mice [37]. The role of tumor-suppressive miRNAs
delivered by EVs was suggested by evidence of their active
transfer to tumor cells, and the abrogation of the biologic
activity of EVs with depleted miRNA [37]. Studies aimed
Endocrine (2013) 44:11–19 15
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at defining the molecular components of EVs responsible
for their biologic actions in different pathological condi-
tions, and understanding the mechanisms involved in spe-
cific packaging of RNAs could subsequently lead to
developing strategies for engineering the contents of EVs
for therapeutic purposes.
Conclusions
EVs are able to alter the behavior of recipient cells by trans-
ferring bioactive molecules to them. EVs released by a given
cell type may function within a defined microenvironment or
may even act at a distance. The exchange of information
between cells by EVs is frequently bidirectional. As EVs
contain molecules which are characteristic of the cell of ori-
gin, they may be exploited as biomarkers. In addition, their
ability to deliver genetic material from stem to tissue-injured
cells can, at least partly, explain the paracrine/endocrine
action of stem cells. Pre-clinical studies suggest that EVs can
reproduce the effect of stem cell treatment, prompting
research to evaluate whether they can be a substitute for cell-
based therapy in regenerative medicine.
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